Found: 8
Select item for more details and to access through your institution.
Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection.
- Published in:
- eLife, 2015, p. 1, doi. 10.7554/eLife.12177
- By:
- Publication type:
- Article
Highly efficacious and safe neutralizing DNA aptamer of SARS-CoV-2 as an emerging therapy for COVID-19 disease.
- Published in:
- Virology Journal, 2022, v. 19, n. 1, p. 1, doi. 10.1186/s12985-022-01943-7
- By:
- Publication type:
- Article
AYA22A Aptamers Mitigate Peanut Allergenicity: Insights from Degranulation Assays and Modulating Immune Responses.
- Published in:
- Allergies (2313-5786), 2024, v. 4, n. 3, p. 94, doi. 10.3390/allergies4030008
- By:
- Publication type:
- Article
Dual Checkpoint Aptamer Immunotherapy: Unveiling Tailored Cancer Treatment Targeting CTLA-4 and NKG2A.
- Published in:
- Cancers, 2024, v. 16, n. 5, p. 1041, doi. 10.3390/cancers16051041
- By:
- Publication type:
- Article
Macrophage-Induced Exacerbation of Nasopharyngeal Inflammatory Lymphocytes in COVID-19 Disease.
- Published in:
- COVID, 2023, v. 3, n. 4, p. 567, doi. 10.3390/covid3040041
- By:
- Publication type:
- Article
High-Affinity Neutralizing DNA Aptamers against SARS-CoV-2 Spike Protein Variants.
- Published in:
- COVID, 2023, v. 3, n. 4, p. 520, doi. 10.3390/covid3040038
- By:
- Publication type:
- Article
New High-Affinity Thrombin Aptamers for Advancing Coagulation Therapy: Balancing Thrombin Inhibition for Clot Prevention and Effective Bleeding Management with Antidote.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 18, p. 2230, doi. 10.3390/cells12182230
- By:
- Publication type:
- Article
Noninvasive nasopharyngeal proteomics of COVID-19 patient identify abnormalities related to complement and coagulation cascade and mucosal immune system.
- Published in:
- PLoS ONE, 2022, v. 17, n. 9, p. 1, doi. 10.1371/journal.pone.0274228
- By:
- Publication type:
- Article